ANAPTYSBIO, INC

ANAPTYSBIO, INC is a clinical-stage biotechnology company that develops immunology therapeutics for autoimmune and inflammatory diseases. The company's clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, which completed a Phase 2b trial for moderate-to-severe rheumatoid arthritis (RA). ANB033, a CD122 antagonist, is in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE). ANB101, a BDCA2 modulator, is in a Phase 1a trial. ANAPTYSBIO, INC also discovered and out-licensed multiple therapeutic antibodies through financial collaborations. These include a PD-1 antagonist, Jemperli (dostarlimab-gxly), licensed to GSK, and an IL-36R antagonist, imsidolimab, licensed to Vanda Pharmaceuticals Inc. The company currently generates revenue from milestones and royalties under its immuno-oncology collaboration with GSK and from license and transition services revenue from its collaboration with Vanda. In September 2025, the company announced plans to explore separating its business into two independent, publicly traded companies. One company is expected to manage the financial collaborations for Jemperli from GSK and imsidolimab from Vanda, focusing on protecting and returning royalty value to shareholders. The other company is expected to be a clinical-stage biotechnology company focused on developing and potentially commercializing innovative therapeutics for autoimmune and inflammatory diseases, including rosnilimab, ANB033, and ANB101. This proposed separation is expected to be completed in the second quarter of 2026.